RE:True ValueIt's an additional cost to take the drug(s) to market but in the greater scheme of things it's a relatively small price to pay. The money wasn't even Antibe's (chronic indication). If a motion has not been brought to the Ontario Courts, this could take
years. If employees are involved Ontario Courts will not allow catastrophic payment terms to creditors. Therefore speculations of imminent failure are unfounded. The money is locked up with Antibe and until ordered to pay
nothing is happening. Both parties know this. Payout could be backloaded to align long-term interests with less risks to both parties. Both Antibe and Nuance win. This is quite obvious. If anyone should be re-ing up at these prices it should be Nuance to double down on their position (convertible). This makes much more sense to Nuance. Now interests are aligned. As time goes on and P2 starts, a rising SP and missed opportunity cost will weigh heavily on Nuance. The longer the payout terms are dragged out, the higher the currency will be to pay once ordered by the Ontario Courts. The P2 results could sway Nuance altogether to transfer the deal to Otena for acute pain. There's no GI ulcers with Otenaproxesul. It has tremendous therapeutic potential for hospital medicine (mortality reduction).
GLTA
mstrmnds wrote: If capital can significantly change the valuation of a company then what's the true valuation of a P2 company in acute pain with a disruptive lead drug?